Mario Ojeda‐Uribe - Concepedia

Author

Mario Ojeda‐Uribe

Also Known As

JH. Bourhis, M Ojeda, M Ojeda-Uribe, M Uribe, M. Ojeda, M. Ojeda Uribe, M. Ojeda-Uribe, M. Ojeda‐Uribe, Mario E Ojeda Uribe, Mario Miguel Ojeda

129

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Hôpital Saint-Louis Centre Hospitalier de Mulhouse Centre Hospitalier Régional et Universitaire de Nancy Centre Hospitalier Universitaire de Tours Inserm

About

Mario Ojeda‐Uribe is an author at Hôpital Saint-Louis specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	1.2K
2	Health Sciences	6	6	250
3	Public Health	2	2	104
4	Blood Transplantation	2	2	40
5	Allergy	1	1	70

Mario Ojeda‐Uribe

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial Vincent Ribrag, Serge Koscielny, Jacques Bosq, The Lancet Lymphoid NeoplasiaSurgical OncologyMedicineDose-dense ChemotherapyCancer Treatment	2016	186
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi, The Lancet Hematological MalignancyBone Marrow FailureMomelotinib Versus DanazolSymptomatic PatientsHematology	2023	164
Cardiac troponin‐I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center Y. Benhamou, Pierre‐Yves Boëlle, B. Baudin, Journal of Thrombosis and Haemostasis ThrombosisCardiovascular DiseaseHematologyPathologyCardiac Troponin‐i	2014	136
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study Tadeusz Robak, Jie Jin, Halyna Pylypenko, The Lancet Oncology Hematological MalignancyFrontline BortezomibLymphoid NeoplasiaTransplantationOncology	2018	132
Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study Jacques Delaunay, Christian Récher, Arnaud Pigneux, Blood	2011	118
M‐CSF (monocyte colony stimulating factor) and M‐CSF receptor expression by breast tumour cells: M‐CSF mediated recruitment of tumour infiltrating monocytes? Ruoping Tang, Mario Ojeda‐Uribe, P Pouillart, Journal of Cellular Biochemistry	1992	99
Administration of rituximab during the first trimester of pregnancy without consequences for the newborn Mario Ojeda‐Uribe, C Gilliot, Georges Jung, Journal of Perinatology First TrimesterMedicineMaternal ComplicationGynecologyMaternal Health	2006	92
A <scp>P</scp>hase 2 study of <scp>L</scp>‐asparaginase encapsulated in erythrocytes in elderly patients with <scp>P</scp>hiladelphia chromosome negative acute lymphoblastic leukemia: The <scp>GRASPALL/GRAALL‐SA</scp>2‐2008 study Mathilde Hunault, Thibaut Leguay, Françoise Huguet, American Journal of Hematology	2015	76
High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia Delphine Réa, Laurence Legros, Emmanuel Raffoux, Leukemia Hematological MalignancyChronic Myeloid LeukemiaMedicineMixed-phenotype Acute LeukemiaImmunology	2006	76
Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities Aurore Perrot, Isabelle Luquet, Arnaud Pigneux, Blood	2011	73

Page 1